Form 424B3 - Prospectus [Rule 424(b)(3)]
15 Agosto 2023 - 5:10AM
Edgar (US Regulatory)
Prospectus Supplement No. 1
Filed Pursuant to Rule 424(b)(3)
File No. 333-273359
SeaStar Medical Holding Corporation
3513 Brighton Blvd,
Suite 410
Denver, CO
80216
(844) 427-8100
Prospectus Supplement No. 1
(to the Prospectus dated August 10, 2023)
This Prospectus
Supplement No. 1 supplements and amends the prospectus dated August 10, 2023 (the Prospectus), relating to the sale from time to time of up to 1,096,972 shares of our common stock by a selling shareholder.
On August 2, 2023, we filed with the U.S. Securities and Exchange Commission the attached Current Report on Form 8-K.
This Prospectus Supplement No. 1 should be read in conjunction with the Prospectus and is
qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement No. 1 supersedes the information contained in the Prospectus.
Our common stock is traded on the Nasdaq Stock Market under the symbol ICU. On August 11, 2023, the last reported sale price of
our common stock was $0.38 per share.
Investing in our common stock involves a high degree of risk. See Risk Factors beginning on page 5 of the Prospectus dated
August 10, 2023.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved
of these securities or determined if this Prospectus Supplement No. 1 is truthful or complete. Any representation to the contrary is a criminal offense.
The date of
this Prospectus Supplement No. 1 is August 15, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2023
SeaStar Medical Holding Corporation
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
|
001-39927 |
|
85-3681132 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
3513 Brighton Blvd,
Suite 410 Denver,
Colorado |
|
80216 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants Telephone Number, Including Area Code: 844
427-8100
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock par value $0.0001 per share |
|
ICU |
|
The Nasdaq Stock Market LLC |
Warrants, each whole warrant exercisable for
one share of Common Stock for $11.50 per share |
|
ICUCW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 4.01 |
Changes in Registrants Certifying Accountant. |
On July 31, 2023, SeaStar Medical Holding Corporation (the Company) was informed by Armanino LLP (Armanino), the Companys current
independent registered public accounting firm, that Armanino would resign as the Companys independent registered public accounting firm effective as of the earlier of (i) the date the Company engages a new independent registered public
accounting firm or (ii) the filing of the Companys quarterly report on Form 10-Q for the fiscal quarter ending September 30, 2023. Armanino advised the Company that its decision to resign was due to
Armaninos transition away from providing financial statement audit services to public companies. In light of Armaninos determination, the Audit Committee of the Companys Board of Directors has initiated a process to select a new
accounting firm to serve as the Companys independent registered public accountant commencing with the audit of the Companys financial statements for the fiscal year ending December 31, 2023.
Armaninos audit reports on the Companys consolidated financial statements as of and for the years ended December 31, 2022 and 2021 did not contain
an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except the audit report for the fiscal year ended December 31, 2022 contained a going concern
explanatory paragraph.
During the years ended December 31, 2022 and 2021, and during the subsequent interim period through July 31, 2023, there were no
(a) disagreements with Armanino on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Armaninos satisfaction, would have caused
Armanino to make reference to the subject matter thereof in connection with its reports for such periods; or (b) reportable events, as described under Item 304(a)(1)(v) of Regulation S-K.
In accordance with Item 304(a)(3) of Regulation S-K, the Company provided Armanino with a copy of the disclosures it
is making in this Current Report on Form 8-K and requested from Armanino a letter addressed to the Securities and Exchange Commission indicating whether it agrees with such disclosures. A copy of
Armaninos letter dated August 2, 2023 is attached as Exhibit 16.1 hereto.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
|
|
|
Exhibit No. |
|
Description |
|
|
16.1 |
|
Letter from Armanino LLP to the Securities and Exchange Commission dated August 2, 2023. |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SeaStar Medical Holding Corporation |
|
|
|
|
|
|
|
|
By: |
|
/s/ Eric Schlorff |
Date: August 2, 2023 |
|
|
|
Name: |
|
Eric Schlorff |
|
|
|
|
Title: |
|
Chief Executive Officer |
Exhibit 16.1
August 2, 2023
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We have read Item 4.01 of the Current Report on
Form 8-K of SeaStar Medical Holding Corporation dated August 2, 2023, which we understand will be filed with the Securities and Exchange Commission, and we agree with the statements concerning our firm
contained in such Form 8-K. We have no basis to agree or disagree with other statements of the registrant contained therein.
Very truly yours,
/s/ Armanino LLP
Armanino LLP
Denver, Colorado
SeaStar Medical (NASDAQ:ICU)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
SeaStar Medical (NASDAQ:ICU)
Gráfica de Acción Histórica
De May 2023 a May 2024